ANGELA ROMANO: Open Payments
NPI 1487810537 · WARSAW, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,521 in 68 payments from 14 companies in 2025. Trend: 2023 $47 · 2024 $2,502 · 2025 $1,521
Food & beverage: $1,514Education: $8
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 8 | $248 |
| Teva Pharmaceuticals USA, Inc. | 11 | $246 |
| Alkermes, Inc. | 14 | $229 |
| Janssen Pharmaceuticals, Inc | 9 | $217 |
| Otsuka America Pharmaceutical, Inc. | 13 | $209 |
| Tris Pharma Inc | 1 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $61 |
| Neurocrine BioSciences, Inc. | 1 | $26 |
| HARMONY BIOSCIENCES LLC | 1 | $24 |
Products named: COBENFY, ARISTADA, UZEDY, INVEGA SUSTENNA, REXULTI, Dyanavel XR, AUSTEDO XR, TRINTELLIX.
Industry payments across IN — which companies pay providers there.
